ANL\t^'A-

Republic of thc Philippines

Dcpafturcut af Healtir
fOO, AI{D DRUG ;\DS{l N lS'l'ltA'l'l(}N

li) \4av ltll2

BURBAU OF INTBRNAL REVBNIE

CAESAII. R. DTJI-AY
(,. r:rrrnissir,ner
.iiureau of Jillerilal l{cvenuc
Quczou Ciry
R.EC
SUBJECT En4orsenrent of ,[ipdated List of VAT-Excmrrt Mcdieincs
Under Republic Act (RA) 11534 knorvn as Cornorate
Recovgry and T4x Incentives for llntcrprises (CREA'I'L) Act

Dear Commissioner Dulav:

With refbre'nce to the Inr1":lcmenting Guidelines ori the Vah.re-Arlclecl 'l"ux $rA"f) Exempliou itn
Srveral He:rlth Producis pl'ovided under Joint Adniinistrative Ordcr fJAO) No. 2-2018 datcd 2i
lJecember 101 I anci JAO Nn^ 2021 -0001 dated 23 June 2021 . nray we provide ,r,orr rvith lhe updates
ro rhe "List of VA'f-Exenlpt Drugs fttr l-lyperlerrsion, Canccr, Menlal illnesses, Tubctculosis,
I(idney' Diseases. Diabetes. and Hig'h Cholestercil". Further, DOH Departrnent l.'lemot'anrlunt No.
:02 l-0380 has been issued. rvherein ail documents with refercnce to the VAT-Exempt lisl oi'alJ
( OVID- I 9 related rledicines and medical devices shall be forwarded to the l lJA. Listed liereunder
lire thc upd;rtes.

Incltrsiort

;1. [lcdicines lbr Cancer

i Ceneric Xarne I)osir Streu _ _ D:, rltie For rtt _

I(cr-.'rrrbinlrri Hl,rrla,,
uooo mL Solution firr IV Injcctron
- ]--.- '! 'o'*
L-ryttrrqpqieti, Ai!4"

B. N{edicines for CO\rID -19 trc:rtment

Dosagc Strength Dosage Form

-Sry:iq*14u!-
50i)m0gr11 (0.05% wiv)
ulicasone Prcpionate

: Azeiastiue
I37 mcg r' 50 mcg per
, ilydrochloridtl i-
actr-ralior.r (Spray)
i Fluticasilne
l.lulicasone - I
125 ntcg Metcred-llosclrrhaicr
i

llirrerernl i
r l

Fluticasone - 250 mcg / ?5 rncg lr'lelcrccl-Dosii Iiilrirlcr

Sahpclelql_.-

L ri'rc Ilri','e. i ilirrvest f'orTorate

frr-lnk Liuc -('3 857 1900:
Ciil Alabans i781 \{rrntinlupa, Pltilippin*s
Firx -i6l 2 807 0751 I .r.-
iA; I
I IUVHlsr,rdrll I
$i:i ltsl!ir15

\\ cbsite : wr-vrr "lda.rcir'.plr Errtail: rnlb,g)1da gor.plt I ;*_X

tlde{Hdfli
 ,1','- nsinrr {irr \ils,rl
i'l ulicasoile liurttate f7.-5 rrr/actr:atinr, Q ,r r.:

Fli;ti;no*'F**t" "
Urrecliuidium ilrt, Irlrvdcr r
(As Broniidel i 100 mcg,' (r1.5 mcg ' i-, rncg
ln lr iilai iort
Vilarrlerol
(.,\s 'l rit.bnatate)

i-ti," Po$,tler l0r

,sc i inhalation

50(] nrc,:/nrl.
I ..11,-;11i;ir-titi i.r' N"-"1 I
r.i.! rrrJ. srr: . S'rt. '

r ,.;,rjllsit:n
ii ot'Nasal i
5()ti r;rcg niL (nt':tr
Fluticasonc Propi i_ \r.1Lrc.rus Ni1.lrl SpraYl
i \,{ctcrcd-Dosclnhalr
Fl uticasonc l"'rouionatc 125 rncg / iic{gsfiirrr I

r\;'rr-CFf',i
-
---* -l_"'
I S'-rsp,:rtsion llr lnhalation
uticasonc Propionate 75a rnlliml (ir,jbuics)
i i

; Su*pcnsion for Nasal

Fi uticasone I'ropionate 50 mcg i A"trutir'',. S prai'
i

i25 mc actuithuit hle:lcrgd Dp

Fluticasonc "ill!*lSL--l
\[) rnr<, I
- Nasal
*-;*,.1
Spray'
l_IJ uticasone Propionate
l
i

I it1 utrcasc,ne Propionate

I 10 nrcg 1,'tr \,lctcrurl llosc Inhaler
n Fot',",nr"tol Fumarate i1..
ZS0 rncg
II i actuatro|l {Suspension)
dihvrate
dr hr:rate .t.-
! -1
i "- _"- .... .."...-....-._J,.---,*
",..-....-._J, .---,"..------*-

Ii Fiuticasone
Fiuticasorre l)ropiottatc
Prcr
\{etered Dose Inlrelcr
\

I ' l;uirrutcrtll i'-umttratc

umulate 50 mcg,'5 tnug per actuittlon (Suspension)
riihldale
Salrnetercll
(as Xinaloatc) l 25 mcg 2-50 ntcg h'leieL;'-. Dose Inhalel
i; i uli g-a9 9r1e--f fqpXUl qe
Salmetetol Metereci l)oie lnhaler
(as Xinafoat$ + 250 mcg
(Suspension)
- flu{gr.:qtq.ry9rgle!9
Salinstsrol
(as Xinafirate) + 25 rncg ' 125 mcg l",fetered Dose initaler
I

Fluticasone
Snlrneterol
(as Xinafoate) + 25 mcg 1 125 ttrcg
;;;;;;;,,;;;;--l
(Suspension)
I

Dry Powdcr firr I

I (.u. Xinaibatc) + 50 mcg 100 r:rcg

Inhalation (iapsrrlc
I

[_! uticirsone Prnpionatc -...-.- l

I Siilmeterol Drr, l'owder fbr 1

(as Xinati:ate) + 250 r':rcg l

Inhalation in Capsulc
f]ulrgelqrc-ryeullels I
I

Sahnctetol U,: l)nvlder hrr

I
t

(as Xinalbatc) + 50 rncg. 500 rncg ]

I inhalation in OaPsrrle
utir:ascxr c Propionalc

BURBAU OF INTERNAT REVENUE

l'illlL ./ \)l 4

2 1 ?Ii;

RECE,I
 Saimeterol
Xirrafbatc) -.
25 rlcg l?-5 nrr:!: t:cr
tAS AInaIOaIC)
{As i
Aetuatiott
I:l iritcasollc l)t't)lirtriiutu :

Sahitclcn:l
Ji lrrrg , 250 mcg per \,letcrcd Dosc lnhalei
{As Xinaiiriite} i
Actuation {CFC Frcc) ( 12.0 doses}
I .rair:reierol
) iAS XIIl3lrrilte ) = i 25 rncg' 125 mcgper
lvletered-Dose lnhal er

Sirlrn cieroi Prcsr l"'izeti Ll c'ier'cd

, (As Xinal'oate) + i :a nlc.{,' l2-i rucg Dose Inhalev i,

uticr.isonc Pr'.llriortatc {Cl'Q !ige)-------,

iffi
1- , .

Prcssurized Metered
.ia iAs Xinafoate) ':- , 25 mcg 250 rr:cg l)erss lnhaler
i Fir:tieasorie Prr:t:iorlat_!' iCFC Free
i salrrrcrcr ol
2-5 mcg. 350 rncg per I"ressu-i-ieed Liquid lbr
(As,Xiriaftralc) +
I ;.,;;;;n M-.t*r",i
Fiuticasorrc Propir;natc. I '--'-".""^' '
'-'- uor" _
lnhalalion
Saimeterol i 25 nicg ' 125 mcg zetl LiqLrid ltrr
-- "'-t'
""'*-**'-' = iI Actuatioir
Ii tAs Xina{bate}
I
Pcr Pru'ssrrt'i

- '.'-
'-E' h,,lctercd f)oss lnhalalion
j Sairneterrll (As -- I

Xinaibate) i Fhiticasorre 250 rncg \,Ictclcrl l)osc

['ropiorrate
Saln:ctcroi
I
Dry Powcler tbr
)
(As Xinali:atc)'l 50 mcg I500 mcg
lnhaiation
l' I utiurso ne I L_o1,U11.Ig
:
Saln:eterol i

I)ry Pr:*iler lrlralation

I

(As Xinatbatel + 50 r::cg

I

Capsule
1

'tr tLrticasone Plopionatl_ j. , I

I

Sairneterol i
25 rncg ' 50 mcg pcr
j iAs Xinafbate) + i
\{rtcrcd l)osc lnltalcr
Actuation
:l ir-iticliso::c Propronatc I

Salmetcrol
Dry Poiuder ibr
i t.qo Xinatlale) * 50 mcg i 1(10 mcg Per dlrse inhalation
ii---.--------'-**"#
Fluticasune Proflionate
i
rl Sahrrctcrol I

Dr; i'owder lirr

I (Au XirT;iftrate) i | 50 rncg
i 250 rncg per dose
Inlralation
i itiuticasone Propionate ''-' ' i '-
,,t :airneteroi t-- :

\'lctcrcd Dosc hrltalcr

'' {A. Xrnali.,atc} = I 15 / 25() lncl ucl'Acrrutiorr
t(r (SL.rspcns;ion)
Fruticasonc Prggr!ffg$_r__
I

r- __
5rl,rr.{".,1----l- -;
15 rttcr.: 150 rncg per
{-'\S -)(lnaI()ate};
, F, utcas.rne l'roniortate i *aclLlatlon
-
i Sahnetcrol i
l)r_y Por.idrr lili
I (as Xin(]tbare) i(10 rrrci ,' "50 nrcg
Inhalatron {DPI)

mcg I25 mcg per

Mctcrud Dosc lrthirlcr
Actuatiorr
Dry Puivder fi.:r
n1"::
$r;;1rrpr,l"t -,-11::' lnhalation (ln Capsule)

ffi
'-it

lage 3 oi -l
 S.,,r;i..,,rol ;iin. ixt;f I)n ilr.:.. ' kir
50 rncg : 2-1{i rrrr.':,
Fltrti, ..,1'itt PI{,lri,rttatr
+---- -.-. r
rnsulcl
S rlrrre terol ,r rtr;rf'oate -
i
rr,. ,' tbr
{(ll I rri, ,,

"I I']gtr:i,sone Propioirat ' '' i,,lr:ilaii

rrrll l.ili(,lr
_1!!4.)---
I

Srrlmricr*i Xinat'oate ;
i \{eteluii Do'': trrhalcr
t,

ltropi
pronatc
25 nrcg '50 mcg
I Fluticasone
'',1Yv::':',-l
i Srrlmeterol Xinaloatc * !r:Ltir;fi L rrhalcr.

' '(rrrrrLLLrur - \rrl*tvurv

i
L
I 50 trrc: i()li titu'-: i''ltticr th ,alation i

Sirlnrelerol Xinatirate -
; 5() rrtr.:q 2 j() rrre.{ I'ir* dcr iot ;iiitliou
Fiuticasorle I'ropionate I
l

, SiSirlrneterol Xinatbate -
50 rrcs ,' 500 mcg i Po,lvder fur ;,rilaiir-rn I

i..,.{ I r-lticason e Propionate I

I

Should you lrave nny cluestionslclarihcations, kindlSr addrcss lhem to titc FD.. i'olicy and
P zinnirtg [i cr:vice al ppsQQtda.go v.ph.
1

l'hank yoll very much.

VerJ'trr-rl.v yours,

IlR. Of T ERREZ, JR.

Ot'licer-i _Di ;tor Gcneral

ffi

P:l1r* .1 c,f 4